反应详情

The title compound was prepared in the same way as that described in Example 11, Step 4, using 5-cyclohexyl-1,3-dihydro-1-methyl-3(R,S)-[(4nitrophenyloxycarbonyl)amino]-2H- 1,4-benzodiazepin-2-one (0.25 g, 0.57 mmol), triethylamine (80 μl, 0.57 mmol), dimethylformamide (5ml) and 1-(ethylsulphonylaminocarbonyl)-3-nitrobenzene (0.14 g, 0.63 mmol). After trituration with hot methanol, the compound (125 mg, 42%) was afforded as a colourless solid. mp 210° C. (dec.). 1H NMR (360 MHz, D6 -DMSO) δ 0.86-0.98 (1H, m), 1.10-1.25 (2H, m), 1.23 (3H, t, J=7.4 Hz), 1.26-1.64 (5H, m), 1.72-1.80 (1H, m), 1.87-1.96 (1H, m), 2.88-2.99 (1H, m), 3.33 (3H, s), 3.48 (2H, q, J=7.4 Hz), 5.08 (1H, d, J=8.3 Hz), 7.31-7.42 (3H, m), 7.47 (1H, d, J=7.9 Hz), 7.52-7.58 (2H, m), 7.67 (1H, dd, J=7.9 and 7.8 Hz), 8.76-8.80 (1H, m), 7.92 (1H, dd, J=1.8 and 1.8 Hz), 9.21 (1H, s), 11.98 (1H, brs).